## SUPPLEMENTAL MATERIAL

## **Supplemental Methods**

Brain MRI protocol and post-processing: Imaging was performed on a dedicated 1.5-T research MRI system (Philips Medical Systems). The time-of-flight MRA was acquired with a field of view 15 cm, 1 mm effective slice thickness, acquisition matrix interpolated to 256 × 228 matrix, flip angle 25 degrees, TR 20 ms and TE 2.7 ms and the FLAIR images with a multisection turbo spin-echo mode with an FOV of 250 mm, rectangular FOV of 80%, acquisition matrix of 192 × 133 scaled to 256 × 256 in reconstruction, 3-mm section thickness with no gap, a TE of 144 ms, a TR of 5500 ms, an inversion recovery delay of 1900 ms, and a flip angle of 90°. The FLAIR image was acquired in the Multi-Slice Turbo Spin Echo (MS-TSE) mode with a field of view of 250 mm, rectangular field of view of 80%, acquisition matrix of 192×133 scaled to 256×256 in reconstruction, 3mm-slice thickness with no gap, an echo time of 144 ms, a repetition time of 5500 ms, an inversion recovery delay of 1900 ms, and a flip angle of 90°.

## **Supplemental Tables:**

Table I: Interactions							
- 75-		Myocardial Infarction	Any stroke	Ischemic stroke	Crypto- genic stroke	Cardio- embolic stroke	Intracranial arterial disease (small and
		Beta estimate, P-value					
Distal cryptogenic	Years on antihypertensives	-0.17 (0.11)	-0.16 (0.007)	-0.17 (0.06)	-0.37 (0.02)	-0.16 (0.19)	-0.01 (0.99)
	Mean # of antihypertensives	-0.88 (0.21)	-0.18 (0.60)	-0.19 (0.61)	0.22 (0.76)	-0.45 (0.50)	0.53 (0.37)
	Years on Hypoglycemics	-0.58 (0.40)	-0.16 (0.08)	-0.13 (0.13)	-0.52 (0.35)	-14.7 (0.99)	-0.10 (0.45)
	Years on statins	-0.05 (0.67)	-0.06 (0.39)	-0.06 (0.42)	-0.18 (0.32)	0.04 (0.74)	-0.06 (0.67)
	Years on antiplatelets	-0.08 (0.13)	-0.04 (0.50)	-0.05 (0.47)	-0.35 (0.12)	0.03 (0.82)	0.05 (0.70)
	Years on anticoagulation	0.08 (0.88)	-0.13 (0.60)	-0.16 (0.56)	0.01 (0.97)	-0.02 (0.93)	-16.2 (0.99)
Distal cardioembolic	Years on antihypertensives	-0.01 (0.97)	-0.21 (0.11)	-0.26 (0.07)	-0.25 (0.99)	-0.35 (0.03)	-0.05 (1.0)
	Mean # of antihypertensives	0.87 (0.35)	-0.46 (0.56)	-0.63 (0.43)	-1.24 (0.99)	-1.30 (0.18)	-0.42 (0.99)
	Years on Hypoglycemics	0.03 (0.80)	-0.04 (0.81)	-0.02 (0.90)	0.04 (1.00)	0.11 (0.53)	-0.05 (0.99)
	Years on statins	0.08 (0.57)	-0.10 (0.41)	-0.12 (0.58)	-0.03 (1.00)	-0.18 (0.23)	-0.06 (0.99)
	Years on antiplatelets	-0.11 (0.52)	0.21 (0.20)	0.17 (0.27)	-0.01 (0.99)	0.11 (0.54)	-0.13 (0.99)
	Years on anticoagulation	0.03 (0.80)	-0.13 (0.27)	-0.17 (0.16)	-0.08 (0.99)	-0.26 (0.05)	-12.6 (0.99)
Intracranial large artery	Years on antihypertensives	-0.08 (0.54)	-0.21 (0.14	-0.23 (0.14)	-0.16 (0.99)	0.02 (0.92)	-1.41 (0.23)
	Mean # of antihypertensives	0.58 (0.51)	-0.20 (0.81)	-0.10 (0.91)	-0.20 (0.99)	-0.10 (0.94)	0.70 (0.73)
	Years on Hypoglycemics	-0.15 (0.54)	0.13 (0.25)	0.12 (0.29)	-0.03 (1.00)	-0.31 (0.04)	-5.53 (0.99)
	Years on statins	0.15 (0.27)	-0.11 (0.48)	-0.09 (0.58)	-0.01 (0.99)	-0.03 (0.83)	-0.06 (0.66)
	Years on antiplatelets	0.06 (0.66)	-0.02 (0.88)	-0.07 (0.65)	-0.12 (0.99)	0.22 (0.39)	-0.35 (0.32)
	Years on anticoagulation	-12.12 (0.99)	1.89 (0.007)	1.71 (0.05)	1.19 (0.99)	2.45 (0.03)	0.12 (0.99)
Isolated penetrating artery	Years on antihypertensives	-0.01 (0.98)	-0.15 (0.10)	-0.14 (0.15)	-0.14 (0.56)	-0.52 (0.05)	0.03 (0.82)
	Mean # of antihypertensives	0.39 (0.72)	-0.51 (0.43)	-0.66 (0.36)	-1.92 (0.38)	-1.63 (0.26)	0.47 (0.60)
	Years on Hypoglycemics	0.31 (0.11)	0.11 (0.31)	0.19 (0.11)	0.20 (0.48)	-0.01 (0.97)	0.20 (0.19)
	Years on statins	0.01 (0.97)	0.02 (0.87)	0.03 (0.79)	-0.09 (0.80)	-0.47 (0.23)	-0.41 (0.07)
	Years on antiplatelets	0.99 (0.12)	0.09 (0.34)	0.14 (0.18)	0.09 (0.76)	-0.12 (0.58)	0.36 (0.12)
	Years on anticoagulation	-20.45 (0.98)	-0.28 (0.36)	-0.43 (0.43)	-19.31 (0.99)	-0.30 (0.46)	-16.3 (0.99)